The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Do we have an informed time scale for the relocation of a system? If the Daresbury system was to be moved to Harley St, would it simply be a matter of transporting and reconnecting the modules, pipework and cabling or would we be looking at many months of alignment, tuning and conditioning?
Excellent article PJT - well spotted.
I think Abbott will have to put their hands a lot deeper into their pockets though.
This will skyrocket on FDA approval and will steadily climb further in the next year or two as applications develop and revenue rises. I don't think too many LTHs would be interested in being barged aside for a measly £10 per share.
This is a totally game changing technology with potential to save thousands of lives and billions of dollars.
All IMHO
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-covid-19-diagnostic-test-using-breath-samples
Maybe this approval will free up the logjam! GLA
Like I said, if we had failed to gain FDA approval, we would have heard by now.
If the application was rejected then I think at least it would galvanise people into more fully exploring what Parsortix could be used for and actively pursuing those applications.
There have been so many game changing discoveries made in the last few years using Parsortix and I think we are approaching a real crisis as cancer sufferers face delays in diagnosis and treatment due to Covid disruption.
Let's hope this equipment can bring prospects of a better outcome to all those struggling with this terrible scourge.
GLA and all IMHO
Many of the reported breakthroughs and findings refer to treatment monitoring and I fail to see how lack of FDA would prevent it being used for that purpose.
This morning's RNS has been a one off use of Parsortix to isolate CTCs and establish a drug target to reduce CTC shedding. Probably not a lot of future revenue from that particular research facility although their findings will be highly important in the battle to reduce the chance of metastasis.
The main revenues will be from labs carrying out routine monitoring of patients undergoing treatment.
My personal feeling is that if FDA were planning to reject the application, we'd have heard by now. All IMHO
You're correct BOJO,
Each time we have a game changing study result (and they've been coming in steadily for years as you point out) the share price kicks up by 5-10% and then trickles back over the next week or so, almost to where it started. Is it just lack of FDA that's keeping the lid on all these potential applications?
Agreed Zebbo,
This is another bombshell finding. TNBC has a very short treatment decision window.
I cannot see why FDA approval would be required to implement this technique. They are using Parsortix to capture the cells which are then observed to determine changes in the CTC structure and hence guide further treatment. Do clinicians shy away from non FDA approved techniques for fear of later difficulties / lawsuits?
I can see no reason why tests could not be offered to those concerned about their health and able to pay, perhaps as part of an annual check up.
The system is capable of so much more in terms of treatment monitoring and guidance, but no doubt there will be much money to be made from small labs pandering to the concerned wealthy. All IMHO
As a strategy for what GL?
Do you wish to add to your holding at a better price, or do you just want to get your prediction on record so that you can once again come back and crow about your astonishing insight in calling the bottom?
I'm sure that lots of serious LTHs on here will have limit buys in place - but they're keeping quiet about it. All IMHO.
That's quite an assumption Oilhead.
Market price action suggests that in these rattled markets, there are better opportunities for Angle speculators to turn a quick buck elsewhere.
Meanwhile, LTHs of Angle now have an opportunity to add to their holdings at a bargain price. All IMHO
Do you have further info Gawd?
Is this an antigen binding detection system that is limited to the capture of non viable epithelial cells? Such systems have their applications, but do not come close to Parsortix which can capture viable epithelial and mesenchymal CTCs ready for all manner of downstream processing. All IMHO.
And it's not just PI s that are fretting and losing patience. De Walden Estates must be getting quite worked up about the delay.
A piece of top end London property, having had tens of millions spent adapting to purpose and now sitting idle must be raising eyebrows and blood pressure at de Walden.
Maybe a jumble sale would go some way to defraying the tens of thousands a month they would expect to receive in rent.
I'm sure de Walden are not being kept in the dark regarding progress.